Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.38 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22202981 | 0.81 | SIGMAR1 (0.42) | SIGMAR1SLC6A4 | |
| SCHEMBL25893969 | 0.79 | — | — | |
| SCHEMBL13272376 | 0.76 | TSHR (0.31) | — | |
| SCHEMBL8973472 | 0.76 | TAAR1 (0.34) | TAAR1SIGMAR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL26077857 | 0.76 | TAAR1 (0.34) | TAAR1SIGMAR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL27805189 | 0.76 | — | — | |
| SCHEMBL27044676 | 0.75 | — | — | |
| SCHEMBL12848593 | 0.75 | ABCB1 (0.30) | — | |
| SCHEMBL12153681 | 0.74 | APAF1 (0.33) | — | |
| SCHEMBL23869542 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10550201-B2 | Antibody-nanoparticle conjugates for the treatment of drug abuse | BIOVENTURES, LLC (US) | 2020-02-04 | — | — | US | disclosed |
| US-20160030593-A1 | ANTIBODY-NANOPARTICLE CONJUGATES FOR THE TREATMENT OF DRUG ABUSE | BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2016-02-04 | — | — | US | disclosed |
| WO-2014160075-A1 | ANTIBODY-NANOPARTICLE CONJUGATES FOR THE TREATMENT OF DRUG ABUSE | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2001081424-A1 | MONOCLONAL ANTIBODY ANTAGONISTS FOR TREATING MEDICAL PROBLEMS ASSOCIATED WITH D-AMPHETAMINE-LIKE DRUGS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10550201-B2 | Antibody-nanoparticle conjugates for the treatment of drug abuse | CES2, SLC6A3, OPRM1 | TAAR1 209/4885SLC18A2 45/4885SIGMAR1 109/4885 |
| US-20160030593-A1 | ANTIBODY-NANOPARTICLE CONJUGATES FOR THE TREATMENT OF DRUG ABUSE | CES2, SLC6A3, OPRM1 | TAAR1 209/4885SLC18A2 45/4885SIGMAR1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.